Source 1primary paper2025MED
Toolkit/drug-eluting and biodegradable stents
drug-eluting and biodegradable stents
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
We concentrate on three principal bioengineered platforms: (3) drug-eluting and biodegradable stents that convert passive luminal scaffolds into active, long-term drug-releasing devices
Usefulness & Problems
Why this is useful
Drug-eluting and biodegradable stents are described as devices that convert passive luminal scaffolds into active, long-term drug-releasing platforms. The review presents them as a principal GI bioengineering platform used with endoscopy.; long-term local drug release; localized gastrointestinal therapy
Source:
Drug-eluting and biodegradable stents are described as devices that convert passive luminal scaffolds into active, long-term drug-releasing platforms. The review presents them as a principal GI bioengineering platform used with endoscopy.
Source:
long-term local drug release
Source:
localized gastrointestinal therapy
Problem solved
These stents aim to provide sustained, localized therapy in the GI tract while avoiding limitations of systemic or oral delivery for localized disease.; turns passive luminal scaffolds into active drug-releasing devices; supports sustained local therapy for gastrointestinal disease
Source:
These stents aim to provide sustained, localized therapy in the GI tract while avoiding limitations of systemic or oral delivery for localized disease.
Source:
turns passive luminal scaffolds into active drug-releasing devices
Source:
supports sustained local therapy for gastrointestinal disease
Problem links
supports sustained local therapy for gastrointestinal disease
LiteratureThese stents aim to provide sustained, localized therapy in the GI tract while avoiding limitations of systemic or oral delivery for localized disease.
Source:
These stents aim to provide sustained, localized therapy in the GI tract while avoiding limitations of systemic or oral delivery for localized disease.
turns passive luminal scaffolds into active drug-releasing devices
LiteratureThese stents aim to provide sustained, localized therapy in the GI tract while avoiding limitations of systemic or oral delivery for localized disease.
Source:
These stents aim to provide sustained, localized therapy in the GI tract while avoiding limitations of systemic or oral delivery for localized disease.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
biodegradationluminal scaffold-based drug depot functionsustained local drug releaseTranslation ControlTechniques
No technique tags yet.
Target processes
manufacturingtranslationInput: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationoperating role: delivery
The use case described depends on therapeutic gastrointestinal endoscopy and on managing drug-device combination development constraints. Long-term biocompatibility and manufacturing are also highlighted as requirements for translation.; requires therapeutic gastrointestinal endoscopy for the integrated local delivery approach described; translation constrained by drug-device combination regulatory pathways
The abstract does not claim that stents eliminate translation barriers such as cost-effectiveness or regulatory complexity.; clinical translation faces long-term biocompatibility, scalable manufacturing, regulatory, and cost-effectiveness challenges
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Drug-eluting and biodegradable stents convert passive luminal scaffolds into active, long-term drug-releasing devices.
The synergy of bioengineered delivery platforms with therapeutic gastrointestinal endoscopy facilitates precise, minimally invasive, and sustained local therapy for gastrointestinal diseases.
Clinical translation of these gastrointestinal bioengineering delivery platforms is challenged by long-term biocompatibility, scalable manufacturing, regulatory pathways for drug-device combinations, and cost-effectiveness.
In situ-forming hydrogels are described as intelligent wound management materials and sustained drug depots for gastrointestinal applications.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug drug-eluting-and-biodegradable-stents
We concentrate on three principal bioengineered platforms: (3) drug-eluting and biodegradable stents that convert passive luminal scaffolds into active, long-term drug-releasing devices
Source:
mechanism or functionsupports
Drug-eluting and biodegradable stents convert passive luminal scaffolds into active, long-term drug-releasing devices.
Source:
platform synergysupports
The synergy of bioengineered delivery platforms with therapeutic gastrointestinal endoscopy facilitates precise, minimally invasive, and sustained local therapy for gastrointestinal diseases.
Source:
translation limitationsupports
Clinical translation of these gastrointestinal bioengineering delivery platforms is challenged by long-term biocompatibility, scalable manufacturing, regulatory pathways for drug-device combinations, and cost-effectiveness.
Source:
Comparisons
Source-stated alternatives
The review contrasts stents with nanoparticle systems and in situ-forming hydrogels.
Source:
The review contrasts stents with nanoparticle systems and in situ-forming hydrogels.
Source-backed strengths
provide long-term drug release; can be integrated with endoscopy for minimally invasive local therapy
Source:
provide long-term drug release
Source:
can be integrated with endoscopy for minimally invasive local therapy
Compared with hydrogels
The review contrasts stents with nanoparticle systems and in situ-forming hydrogels.
Shared frame: source-stated alternative in extracted literature
Strengths here: provide long-term drug release; can be integrated with endoscopy for minimally invasive local therapy.
Relative tradeoffs: clinical translation faces long-term biocompatibility, scalable manufacturing, regulatory, and cost-effectiveness challenges.
Source:
The review contrasts stents with nanoparticle systems and in situ-forming hydrogels.
Compared with in situ-forming hydrogels
The review contrasts stents with nanoparticle systems and in situ-forming hydrogels.
Shared frame: source-stated alternative in extracted literature
Strengths here: provide long-term drug release; can be integrated with endoscopy for minimally invasive local therapy.
Relative tradeoffs: clinical translation faces long-term biocompatibility, scalable manufacturing, regulatory, and cost-effectiveness challenges.
Source:
The review contrasts stents with nanoparticle systems and in situ-forming hydrogels.
Ranked Citations
- 1.